Aine Hanly, Ph.D., serves as Chief Technology Officer at Vir Biotechnology, where she is responsible for overseeing the Company’s technical operations. Her purview includes product and process development, supply chain, manufacturing, quality and CMC strategy. Her career in the biomanufacturing industry, which has spanned roles in the UK, Ireland and the US, has been dedicated to advancing innovative solutions to accelerate the delivery of medicines to patients.
Prior to joining Vir, Dr. Hanly served as the Vice President of Process Development for Amgen, accountable for clinical manufacturing and global supply of clinical trial materials. During her nearly decade-long tenure, she led teams enabling the commercialization of Amgen’s pipeline products as well as providing technical support for ongoing commercial manufacturing operations. Additionally, as site head at Amgen’s Cambridge facility, Dr. Hanly led the site’s transformation and staff growth, and together with the research and development team, greatly increased Amgen’s partnerships and presence within the local Cambridge ecosystem. She also worked for more than 10 years at Pfizer (formerly, Wyeth), where she held roles of increasing responsibility in analytical R&D, process development, quality and product supply strategy.
Dr. Hanly received her bachelor’s degree in biological chemistry and a Ph.D. in physical organic chemistry, from the University of Ulster, Northern Ireland. She completed her post-doctoral fellowship at Creighton University School of Medicine before joining the collaborative research wing at Yale University and CuraGen Corporation as lead scientist studying gene isolation and subsequent confirmation using a variety of molecular biology techniques.
What is Ann M. Hanly's net worth?
The estimated net worth of Ann M. Hanly is at least $1.29 million as of April 1st, 2024. Dr. Hanly owns 132,069 shares of Vir Biotechnology stock worth more than $1,285,031 as of May 19th. This net worth approximation does not reflect any other investments that Dr. Hanly may own. Additionally, Dr. Hanly receives an annual salary of $896,070.00 as CTO at Vir Biotechnology. Learn More about Ann M. Hanly's net worth.
How old is Ann M. Hanly?
Dr. Hanly is currently 54 years old. There are 4 older executives and no younger executives at Vir Biotechnology. The oldest executive at Vir Biotechnology is Dr. Lawrence Corey M.D., Co-Founder & Scientific Advisor, who is 76 years old. Learn More on Ann M. Hanly's age.
What is Ann M. Hanly's salary?
As the CTO of Vir Biotechnology, Inc., Dr. Hanly earns $896,070.00 per year. There are 2 executives that earn more than Dr. Hanly. The highest earning executive at Vir Biotechnology is Dr. Marianne De Backer M.B.A., M.Sc., Ph.D., CEO & Director, who commands a salary of $4,470,000.00 per year. Learn More on Ann M. Hanly's salary.
How do I contact Ann M. Hanly?
Has Ann M. Hanly been buying or selling shares of Vir Biotechnology?
During the last ninety days, Ann M. Hanly has sold $27,245.55 in Vir Biotechnology stock. Most recently, Ann M. Hanly sold 2,711 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $10.05, for a transaction totalling $27,245.55. Following the completion of the sale, the executive vice president now directly owns 132,069 shares of the company's stock, valued at $1,327,293.45. Learn More on Ann M. Hanly's trading history.
Who are Vir Biotechnology's active insiders?
Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?
In the last twelve months, insiders at the sold shares 23 times. They sold a total of 688,972 shares worth more than $15,517,627.33. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 15.6% of the company.
Learn More about insider trades at Vir Biotechnology. Information on this page was last updated on 4/3/2024.
